PharmaFocus Today – Page 209 – media

The Nation’s First Stem Cell Drug Production License Issued Cell Therapy Track to Meet the Development Opportunities

Beijing Drug Administration held a half-year working meeting, at which the work of issuing the country’s first stem cell “drug production license” was particularly recognized. According to the search results of “Administrative License Information” on the website of Beijing Drug Administration, Platinum Bio-Excellence Biotechnology (Beijing) Co., Ltd. is the first company to obtain the national stem cell drug production license. The issuance of the Drug Manufacturing License is of epoch-making significance as it is the first drug manufacturing license specifically for stem cell drugs in China. The issuance of the Drug Manufacturing License signifies that the relevant enterprise has obtained the legal qualification and ability to manufacture stem cell drugs. In recent years, with the introduction of policies such as the “14th Five-Year Plan” for the development of bio-economy, China has clearly put forward the development of new technologies such as stem cell therapy, strengthening the synergy between industry, academia, ...
- Source: drugdu
- 339
- September 2, 2024
HEC Pharmaceuticals and Shamshi Technology held a joint laboratory unveiling ceremony

On August 28, 2024, HEC Pharmaceuticals and Deepin Technology held a joint laboratory unveiling ceremony. The joint laboratory of HEC Pharmaceuticals and Deepin Technology focuses on high-value R&D scenarios and technical R&D bottlenecks in the field of biopharmaceuticals, promoting science and technology from The complete closed loop from source innovation to industrial implementation forms a complete closed loop, jointly exploring the industrial transformation and verification of cutting-edge AI technologies. The unveiling ceremony announced the cooperation relationship between the two parties and promoted close cooperation between the two parties in future multi-level projects. Co., Ltd. (hereinafter referred to as East Sunshine Pharmaceutical), as the domestic anti-influenza “top” brand, its anti-influenza drug Kewei® is the top brand of oseltamivir phosphate, and in February this year, it was awarded the The company has obtained three certifications: “the largest oseltamivir production base in the world”, “the largest oseltamivir production in the world in the ...
- Source: drugdu
- 185
- September 1, 2024
First domestic generic! Jimin Kexin’s Ropinirole Hydrochloride Sustained-Release Tablets approved for marketing

Nanjing Hengsheng Pharmaceutical Co., Ltd. (hereinafter referred to as “Nanjing Hengsheng”), a subsidiary of Jimin Trustworthy Group, received the “Drug Registration Certificate” approved and issued by the National Medical Products Administration (NMPA), approving the company’s ropinirole hydrochloride sustained-release tablets (specification: 2mg) for sale. This variety is the first generic drug of ropinirole hydrochloride sustained-release tablets approved for sale in China. It is mainly used to treat patients with Parkinson’s disease in the early, middle and late stages and non-motor symptoms. It is developed by the Innovative Technology Drug Research Institute under Jimin Trustworthy Group and Nanjing Hengsheng is in production. Parkinson’s disease is a common degenerative disease of the elderly nervous system. Symptoms include resting tremor, muscle rigidity, bradykinesia, cognitive impairment, etc. The condition worsens over time, causing great burdens on patients’ families and society. Ropinirole hydrochloride is a new dopamine receptor agonist that can enter the central nervous system ...
- Source: drugdu
- 203
- September 1, 2024
Vice President Wang Maochun paid a working visit to the China Center for Assistive Devices for Persons with Disabilities

On the morning of August 9, Vice President Wang Maochun and his delegation paid a working visit to the China Center for Assistive Devices for Persons with Disabilities, and had pragmatic exchanges with Kong Deming, Secretary of the Party Branch and Director of the Center, on the development of the assistive device industry and the participation of Chinese assistive device companies in international cooperation. The Chamber of Commerce’s External Cooperation Department and Exhibition Department accompanied the meeting. Vice President Maochun briefly introduced the basic situation of the Medical Insurance Chamber of Commerce in helping domestic pharmaceutical companies to develop internationally over the years, and highly appreciated the contributions of the Assistive Devices Center in promoting the distribution of assistive device products and improving the level of technological research and development innovation. He said that the Medical Insurance Chamber of Commerce is willing to work with the Assistive Devices Center to ...
- Source: drugdu
- 235
- September 1, 2024
Tonghua Jinma Oral Drug Succinium Octahydroaminoacridine Tablets Listing Application Accepted

On the evening of August 29, Tonghua Jinma announced that the company recently received the State Drug Administration issued a listing application for succinium octahydroaminoacridine tablets “Notice of Acceptance”, the oral drug for light, moderate Alzheimer’s disease (Alzheimer’s disease, AD) treatment. On the same day, Tonghua Jinma plate rushed to a halt, closing up 9.98%, closing price of 14.54 yuan / share. Alzheimer’s disease as one of the most common neurodegenerative diseases, the number of its patients with the aging trend of the population and rising. According to the introduction, Succinum Octahydroaminoacridine Tablets is a new, potent, clear mechanism of action of cholinesterase inhibitors, is a new chemical 1 class of drugs with complete independent intellectual property rights, new chemical molecular structure, domestic and foreign have not been marketed. The results of the main pharmacodynamic study show that the drug exhibits strong inhibition of both acetylcholinesterase and butyrylcholinesterase, and by ...
- Source: drugdu
- 387
- September 1, 2024
Analysis and Prospect of Import and Export Situation of Raw Materials in the First Half of 2024

In the first half of 2024, the total import and export volume of raw materials in China reached 26.52 billion US dollars, a year-on-year increase of 0.6%. Among them, the export value was 21.34 billion US dollars, a slight increase of 0.1% year-on-year; The import volume was 5.18 billion US dollars, a year-on-year increase of 2.8%. 1. Overall Overview and Trend Analysis As the main raw material products in the category of Western medicine import and export products in China, active pharmaceutical ingredients account for 50% of Western medicine foreign trade. From the perspective of exports alone, raw materials account for 80% of the export of Western medicine products. From the import and export situation since 2021, it can be seen that the global demand for active pharmaceutical ingredients has rapidly increased due to the epidemic. In 2022, the foreign trade of active pharmaceutical ingredients reached a historical high, with ...
- Source: drugdu
- 524
- August 31, 2024
Fulbright Medicalwithdraws its application for issuance and listing

On August 23rd, the IPO review status of Jiangsu Fulbright Medical Equipment Co., Ltd. (referred to as Fulbright Medical) on the Science and Technology Innovation Board of the Shanghai Stock Exchange changed to “terminated”. Due to the withdrawal of the issuance and listing application by Fulbright Medical and its sponsor, in accordance with Article 63 of the Shanghai Stock Exchange’s Stock Issuance and Listing Review Rules, the Shanghai Stock Exchange has terminated its issuance and listing review. The Shanghai Stock Exchange issued an inquiry letter on July 23, 2023 regarding the review of the application documents for the initial public offering and listing of Jiangsu Fulbright Medical Equipment Co., Ltd. on the Science and Technology Innovation Board, requiring Fulbright Medical to respond to multiple questions regarding its main products, market, volume based procurement, core technology, and more. On January 17, 2024, Fulbright Medical updated its response to the first round ...
- Source: drugdu
- 278
- August 31, 2024
Chongqing’s first Class 1 innovative biological drug is launched

On August 27, Chongqing’s first Class 1 biological innovative drug, Celici monoclonal antibody injection, was approved for marketing, achieving a “zero” breakthrough in Chongqing’s biological product innovative drug track. According to Zhixiang Jintai’s official microblog, Celici monoclonal antibody injection is its first product approved for marketing and the first fully human IL-17A target drug in China. Indications for the birth of the “king of medicine” Moderate to severe plaque psoriasis as an indication is regarded as the “Gold Coast” in the field of autoimmune indications. The former “king of medicine” Humira was born from it. Due to the complexity of the psoriasis pathway itself, there are also many antigens that can be targeted in the pathway. The more typical one is the previous generation of “king of medicine” Humira. Adalimumab is a monoclonal antibody targeting TNF-α. This target has a wide range of adaptability for autoimmune diseases. Its indications range ...
- Source: drugdu
- 303
- August 31, 2024
Treatment of small cell lung cancer enters a period of accelerated breakthroughs

In the field of tumors, any breakthrough is not easy. Although humans have discovered cancer for a long time, chemotherapy has long been the core treatment method. Of course, after countless failures and dashed hopes, once there is a breakthrough, the progress is often unexpected. For example, after decades of silence, the treatment of small cell carcinoma seems to have ushered in a period of accelerated breakthroughs. On August 15, AstraZeneca announced that its drug durvalumab has been accepted by the FDA for the indication of limited small cell lung cancer (LS-SCLC). If approved for marketing, this will be the first immunotherapy in 40 years to show survival benefits in this field, representing an important breakthrough. For limited-stage SCLC, the current first-line treatment is still chemoradiotherapy, especially the treatment of cisplatin combined with etoposide, which occupies an absolute dominant position in treatment. Amgen has also made progress in the field ...
- Source: drugdu
- 363
- August 31, 2024
Internet healthcare is more than just selling drugs

Can the business model of Internet healthcare work without selling drugs? This may be the answer that everyone wants to know at the moment. After all, Internet healthcare is recognized as a tough nut to crack. Many entrants have fallen halfway, and some survivors are not in a good situation. Ping An Health’s latest semi-annual report finally gave a definite answer. In the first half of the year, Ping An Health’s adjusted net profit reached 89.74 million yuan, a year-on-year loss of 340 million yuan. This achievement was not easy to come by. Ten years after its establishment, Ping An Health finally achieved its first profit; if compared with JD Health and Ali Health, Ping An Health’s turnaround time is also later, but the latter’s turnaround may be more meaningful to the entire Internet healthcare. The core is that, in the eyes of the outside world, whether it is JD ...
- Source: drugdu
- 198
- August 31, 2024

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.